Rationality and economic evaluation of Compound amino acid injection （14AA-SF） in the perioperative period of neurosurgery
- VernacularTitle:神经外科围手术期使用复方氨基酸注射液（14AA-SF）的合理性和经济性评价
- Author:
Hai LIANG
1
;
Jingjing WANG
1
;
Huijuan CHEN
1
;
Runan XIA
1
;
Panpan DI
1
;
Mengyu JIANG
1
;
Fanqin LI
1
;
Jinghe MA
2
Author Information
1. Dept. of Pharmacy，People’s Hospital of Bozhou，Anhui Bozhou 236800，China
2. Dept. of Critical Care Medicine，People’s Hospital of Bozhou，Anhui Bozhou 236800，China
- Publication Type:Journal Article
- Keywords:
rational drug use;
cost-effectiveness;
nutritional therapy;
attribute hierarchical model;
neurosurgery;
perioperative period
- From:
China Pharmacy
2026;37(17):2303-2309
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To establish standards for the rational use of Compound amino acid injection （14AA-SF） （hereinafter referred to as “14AA-SF”）， and evaluate its rationality and cost-effectiveness.METHODS The standards for the rational use of 14AA-SF were established based on the Delphi method. Archived medical records of patients who used 14AA-SF in the Dept. of Neurosurgery of People’s Hospital of Bozhou from January 2024 to December 2025 were randomly selected. On the basis of the established standards for the rational use， the attribute hierarchical model was applied to evaluate the use rationality of 14AA-SF in the included medical records. The decision tree model was applied to calculate the incremental cost-effectiveness ratio （ICER）， so as to evaluate the cost-effectiveness of 14AA-SF administered via single-bottle infusion versus “all-in-one” infusion， and the robustness of the cost-effectiveness evaluation results was verified through sensitivity analysis.RESULTS A total of 205 medical records were collected， among which 163 records （79.51%） were qualified with medical record score （MRS） ≥90， and 42 records （20.49%） were unqualified with MRS ＜90. The main irrational types of 14AA-SF use included unreasonable infusion method （67 case-times， accounting for 32.68%）， unreasonable amino acid dosage （62 case-times， accounting for 30.24%） and unreasonable non-protein calorie-nitrogen ratio （55 case-times， accounting for 26.83%）. Compared wtih single-bottle infusion， the incremental cost of “all-in-one” infusion for each 1% increase in effective rate was 165.40 yuan. The one-way sensitivity analysis showed that the effective rate of single-bottle infusion had the greatest impact on ICER. The probabilistic sensitivity analysis showed that under the willingness-to-pay （WTP） threshold （89 358 yuan） set in this study， the cost-effectiveness probability of “all-in-one” infusion relative to single-bottle infusion was 89.9%. When the WTP threshold exceeds 17 871.60 yuan， the “all-in-one” infusion is more cost-effective than the single-bottle infusion.CONCLUSIONS The established standards for the rational use of 14AA-SF are practical and feasible. There are phenomena of irrational use of 14AA-SF in Dept. of Neurosurgery of the hospital in terms of indications， nutritional risk screening， infusion methods and other aspects， which need to be further standardized. The “all-in-one” infusion is more cost-effective than the single-bottle infusion.
